Aquino V.R.,Hospital Of Clinicas Of Porto Alegre Hcpa |
Aquino V.R.,Federal University of Rio Grande do Sul |
Vercosa E.B.,Federal University of Rio Grande do Sul |
Falhauber G.,HCPA |
And 5 more authors.
Brazilian Journal of Infectious Diseases | Year: 2010
Very limited data are available in the literature to elucidate the aetiology of invasive mould infections in Latin America. Here we report that Aspergillus species caused only half of such cases in a cohort study conducted over 21 months in a university hospital in Porto Alegre, Southern Brazil. Fusarium spp. were the second most prevalent moulds (20.7%), followed by Zygomycetes (13.8%). The importance of obtaining local epidemiological data for adequately guiding empirical antifungal therapy is reinforced. ©Elsevier Editora Ltda.
Finazzi G.,Haematology |
Vannucchi A.M.,University of Florence |
Martinelli V.,University of Naples Federico II |
Ruggeri M.,San Bortolo Hospital |
And 14 more authors.
British Journal of Haematology | Year: 2013
Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia vera (PV), unresponsive to the maximum tolerated doses (MTD) of hydroxycarbamide (HC), were treated with Givinostat (50 or 100 mg/d) in combination with MTD of HC. The European LeukaemiaNet response criteria were used to assess the primary endpoint after 12 weeks of treatment. Complete or partial response was observed in 55% and 50% of patients receiving 50 or 100 mg of Givinostat, respectively. Control of pruritus was observed in 64% and 67% of patients in the 50 and 100 mg groups, respectively. The combination of Givinostat and HC was well tolerated: eight patients (18%) discontinued, four in each treatment arm; grade 3 adverse events were reported in one patient (4·5%) in each treatment arm. The combined use of Givinostat and HC was safe and clinically effective in HC-unresponsive PV patients. © 2013 John Wiley & Sons Ltd.